September 9, 2026
On September 4, 2026, the Food and Drug Administration published "Advancing Development of Botanical Drug Products; Request for Information" in the Federal Register (91 FR 56887, FR Doc. 2026-18133, Docket No. FDA-2026-N-9550). Comments are due November 3, 2026, by 11:59 p.m. Eastern on regulations.gov. The three-page notice never uses the word cannabis. It does not need to: the botanical pathway is the only drug-approval route a whole-plant cannabis extract can travel, and this is the first open federal invitation in years to say how that route should work.
An RFI is not guidance and not a rule. It opens a public docket so the agency can build a comment record before it drafts anything. This one is signed by Deputy Commissioner Grace R. Graham and framed around a single admission: "the inherent heterogeneity of botanicals creates unique challenges in research, product development, and regulatory review." FDA's answer to that problem until now has been the "Botanical Drug Development" guidance finalized December 29, 2016 (81 FR 96018), which the notice says developers still find hard to satisfy on trial design, production consistency and quality control.
The questions are specific. FDA wants to hear about challenges in studies of healthy volunteers versus patients; about the regulatory difference between "minimally purified or whole plant products versus highly purified or isolate products"; about "quality frameworks to address batch-to-batch variability"; about "scientifically credible study designs … best suited for complex botanical mixtures"; and about how "well-established use, generally accepted scientific knowledge, and/or real-world evidence" could be used to speed development. Each of those is a question cannabis sponsors have been asking since 2018.
By FDA's own count in the notice, only four botanical products have ever been approved as prescription drugs: three NDAs (sinecatechins, crofelemer and birch triterpenes) and one BLA (anacaulase-bcdb). Epidiolex is not on that list. It was approved as a conventional NDA for a purified single molecule, cannabidiol, and that is the point: a purified-isolate strategy gets through today's system, and a full-spectrum extract does not. The RFI's isolate-versus-whole-plant question is the first time the agency has asked the cannabis question in cannabis-neutral language.
The timing is what makes it a compliance matter rather than a policy curiosity. The DEA rescheduling proceeding (Docket DEA-1362) closed its hearing record in August; post-hearing briefs are in, and the administrative law judge has no deadline for a recommended decision. The botanical comment record therefore closes on November 3, before anyone knows whether cannabis will be a Schedule III drug. A Schedule III world without a workable botanical pathway is a world in which only purified-molecule NDAs get through — and the arguments against that outcome have to be in this docket, not the next one.
Nothing in the RFI binds FDA. The agency can revise the 2016 guidance, issue new guidance, or do nothing. What the docket does is fix the evidentiary baseline: when a revision is drafted, the comments on file are what the drafters cite. The notice also points to a recent Reagan-Udall Foundation roundtable on botanical drug development, whose participants flagged real-world evidence, quality frameworks for variability and "increasing education and outreach" as the opportunities to pursue. Those are the themes a comment should speak to.
The international track runs in parallel. FDA and the European Medicines Agency will hold a joint workshop, "Regulatory Perspectives on Herbal Medicinal/Botanical Drug Product Development," on September 25, 2026, at EMA headquarters in Amsterdam with virtual attendance (4:00–7:00 a.m. Eastern). FDA's own event page says the two regulators "share core principles" but have "meaningful differences in their respective regulatory frameworks." The EU's well-established-use route for herbal medicinal products is exactly the concept FDA's last RFI question asks about.
This docket is about the drug door. It does not touch the food and supplement door, where FDA's CBD enforcement policy remains under OIRA review and the Human Foods Program's CBD guidance governs what a hemp brand can put in a gummy. Two agencies, two doors, and a third being negotiated in Europe: the EMA's herbal framework already recognizes well-established use, the concept FDA is only now asking about, and the UK has routed CBD through a food-authorisation process rather than a drug one. U.S. sponsors filing in this docket are effectively arguing for a fourth option — a drug pathway built for mixtures — and the post-Loper Bright limits on agency discretion mean any guidance that results will be read against the statute more strictly than the 2016 version was. For how the drug door interacts with state programs, see medical versus recreational cannabis after rescheduling and the Schedule III tax playbook. The federal hemp definition changing on December 11 — mapped in our state-by-state deadline guide — governs the ingredient side of the same products.
| Conventional NDA (purified molecule) | Botanical drug product (NDA/BLA) | Food / dietary supplement | |
|---|---|---|---|
| Governing framework | FD&C Act §505; ICH quality guidance | FD&C Act §505 plus 2016 Botanical Drug Development guidance | FD&C Act food provisions; DSHEA; FDA enforcement discretion for CBD |
| Evidence standard | Adequate and well-controlled trials on a defined active | Same statutory standard, applied to a complex mixture; RFI asks how | Safety (GRAS / NDI), no efficacy claims |
| CMC expectation | Single characterized active, tight specifications | Whole-extract characterization, batch consistency, marker compounds | cGMP for food or supplements; COA-driven |
| Cannabis example | Epidiolex (purified CBD, 2018) | None approved; whole-plant extracts would travel this route | Hemp CBD gummies and tinctures sold under enforcement discretion |
| Who is asking now | — | FDA, Docket FDA-2026-N-9550, comments due Nov. 3 | FDA Human Foods Program; state hemp regulators |
What is a botanical drug product under FDA rules?
A drug product that includes or is derived from plant materials, algae, macroscopic fungi or combinations of them and is intended to diagnose, treat or prevent disease. FDA's 2016 "Botanical Drug Development" guidance governs how such products are characterized and studied.
Does the FDA botanical drug RFI apply to cannabis?
The notice does not name cannabis, but whole-plant cannabis extracts are botanical drug candidates. Purified CBD (Epidiolex) was approved as a conventional NDA, not as a botanical product, and is not among the four botanical approvals FDA lists.
When are comments due on Docket FDA-2026-N-9550?
November 3, 2026, at 11:59 p.m. Eastern via regulations.gov. Paper submissions must be received by that date.
How is this different from FDA's CBD food and supplement policy?
This docket concerns the drug-approval pathway for complex botanical mixtures. CBD in foods and supplements is governed by FDA's separate enforcement discretion and the Human Foods Program.
This is regulatory journalism, not legal advice — talk to your counsel.
On September 4, 2026, the Food and Drug Administration published "Advancing Development of Botanical Drug Products; Request for Information" in the Federal Register (91 FR 56887, FR Doc. 2026-18133, Docket No. FDA-2026-N-9550). Comments are due November 3, 2026, by 11:59 p.m. Eastern on regulations.gov. The three-page notice never uses the word cannabis. It does not need to: the botanical pathway is the only drug-approval route a whole-plant cannabis extract can travel, and this is the first open federal invitation in years to say how that route should work.
An RFI is not guidance and not a rule. It opens a public docket so the agency can build a comment record before it drafts anything. This one is signed by Deputy Commissioner Grace R. Graham and framed around a single admission: "the inherent heterogeneity of botanicals creates unique challenges in research, product development, and regulatory review." FDA's answer to that problem until now has been the "Botanical Drug Development" guidance finalized December 29, 2016 (81 FR 96018), which the notice says developers still find hard to satisfy on trial design, production consistency and quality control.
The questions are specific. FDA wants to hear about challenges in studies of healthy volunteers versus patients; about the regulatory difference between "minimally purified or whole plant products versus highly purified or isolate products"; about "quality frameworks to address batch-to-batch variability"; about "scientifically credible study designs … best suited for complex botanical mixtures"; and about how "well-established use, generally accepted scientific knowledge, and/or real-world evidence" could be used to speed development. Each of those is a question cannabis sponsors have been asking since 2018.
By FDA's own count in the notice, only four botanical products have ever been approved as prescription drugs: three NDAs (sinecatechins, crofelemer and birch triterpenes) and one BLA (anacaulase-bcdb). Epidiolex is not on that list. It was approved as a conventional NDA for a purified single molecule, cannabidiol, and that is the point: a purified-isolate strategy gets through today's system, and a full-spectrum extract does not. The RFI's isolate-versus-whole-plant question is the first time the agency has asked the cannabis question in cannabis-neutral language.
The timing is what makes it a compliance matter rather than a policy curiosity. The DEA rescheduling proceeding (Docket DEA-1362) closed its hearing record in August; post-hearing briefs are in, and the administrative law judge has no deadline for a recommended decision. The botanical comment record therefore closes on November 3, before anyone knows whether cannabis will be a Schedule III drug. A Schedule III world without a workable botanical pathway is a world in which only purified-molecule NDAs get through — and the arguments against that outcome have to be in this docket, not the next one.
Nothing in the RFI binds FDA. The agency can revise the 2016 guidance, issue new guidance, or do nothing. What the docket does is fix the evidentiary baseline: when a revision is drafted, the comments on file are what the drafters cite. The notice also points to a recent Reagan-Udall Foundation roundtable on botanical drug development, whose participants flagged real-world evidence, quality frameworks for variability and "increasing education and outreach" as the opportunities to pursue. Those are the themes a comment should speak to.
The international track runs in parallel. FDA and the European Medicines Agency will hold a joint workshop, "Regulatory Perspectives on Herbal Medicinal/Botanical Drug Product Development," on September 25, 2026, at EMA headquarters in Amsterdam with virtual attendance (4:00–7:00 a.m. Eastern). FDA's own event page says the two regulators "share core principles" but have "meaningful differences in their respective regulatory frameworks." The EU's well-established-use route for herbal medicinal products is exactly the concept FDA's last RFI question asks about.
This docket is about the drug door. It does not touch the food and supplement door, where FDA's CBD enforcement policy remains under OIRA review and the Human Foods Program's CBD guidance governs what a hemp brand can put in a gummy. Two agencies, two doors, and a third being negotiated in Europe: the EMA's herbal framework already recognizes well-established use, the concept FDA is only now asking about, and the UK has routed CBD through a food-authorisation process rather than a drug one. U.S. sponsors filing in this docket are effectively arguing for a fourth option — a drug pathway built for mixtures — and the post-Loper Bright limits on agency discretion mean any guidance that results will be read against the statute more strictly than the 2016 version was. For how the drug door interacts with state programs, see medical versus recreational cannabis after rescheduling and the Schedule III tax playbook. The federal hemp definition changing on December 11 — mapped in our state-by-state deadline guide — governs the ingredient side of the same products.
| Conventional NDA (purified molecule) | Botanical drug product (NDA/BLA) | Food / dietary supplement | |
|---|---|---|---|
| Governing framework | FD&C Act §505; ICH quality guidance | FD&C Act §505 plus 2016 Botanical Drug Development guidance | FD&C Act food provisions; DSHEA; FDA enforcement discretion for CBD |
| Evidence standard | Adequate and well-controlled trials on a defined active | Same statutory standard, applied to a complex mixture; RFI asks how | Safety (GRAS / NDI), no efficacy claims |
| CMC expectation | Single characterized active, tight specifications | Whole-extract characterization, batch consistency, marker compounds | cGMP for food or supplements; COA-driven |
| Cannabis example | Epidiolex (purified CBD, 2018) | None approved; whole-plant extracts would travel this route | Hemp CBD gummies and tinctures sold under enforcement discretion |
| Who is asking now | — | FDA, Docket FDA-2026-N-9550, comments due Nov. 3 | FDA Human Foods Program; state hemp regulators |
What is a botanical drug product under FDA rules?
A drug product that includes or is derived from plant materials, algae, macroscopic fungi or combinations of them and is intended to diagnose, treat or prevent disease. FDA's 2016 "Botanical Drug Development" guidance governs how such products are characterized and studied.
Does the FDA botanical drug RFI apply to cannabis?
The notice does not name cannabis, but whole-plant cannabis extracts are botanical drug candidates. Purified CBD (Epidiolex) was approved as a conventional NDA, not as a botanical product, and is not among the four botanical approvals FDA lists.
When are comments due on Docket FDA-2026-N-9550?
November 3, 2026, at 11:59 p.m. Eastern via regulations.gov. Paper submissions must be received by that date.
How is this different from FDA's CBD food and supplement policy?
This docket concerns the drug-approval pathway for complex botanical mixtures. CBD in foods and supplements is governed by FDA's separate enforcement discretion and the Human Foods Program.
This is regulatory journalism, not legal advice — talk to your counsel.
